{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T18:59:54Z","timestamp":1782327594347,"version":"3.54.5"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.semnephrol.2014.10.002","type":"journal-article","created":{"date-parts":[[2014,12,17]],"date-time":"2014-12-17T21:46:25Z","timestamp":1418852785000},"page":"660-668","source":"Crossref","is-referenced-by-count":19,"title":["The Uses and Abuses of Vitamin D Compounds in Chronic Kidney Disease\u2013Mineral Bone Disease (CKD\u2013MBD)"],"prefix":"10.1016","volume":"34","author":[{"given":"D.J.A.","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.A.","family":"Massy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Brandenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2014.10.002_bib1","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(14)60384-6","article-title":"Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure","volume":"383","author":"Ortiz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJM197403282901301","article-title":"Accelerated atherosclerosis in prolonged maintenance hemodialysis","volume":"290","author":"Lindner","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib3","doi-asserted-by":"crossref","first-page":"e004251","DOI":"10.1136\/bmjopen-2013-004251","article-title":"Mortality in chronic kidney disease and renal replacement therapy: a population-based cohort study","volume":"4","author":"Neovius","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1742-1241.2012.02954.x","article-title":"Cardiovascular disease in chronic kidney disease: untying the Gordian knot","volume":"67","author":"Hajhosseiny","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib5","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/ndt\/gft514","article-title":"on Behalf of the CKD-MBD Working Group of ERA-EDTA. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?","volume":"29","author":"Cozzolino","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrneph.2011.53","article-title":"Mineral metabolism and vitamin D in chronic kidney disease--more questions than answers","volume":"7","author":"Goldsmith","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib7","first-page":"1","article-title":"The trials and tribulations of vitamin D: time for the \u2018sunshine\u2019 vitamin to come in out of the cold \u2013 or just more broken promises?","volume":"1","author":"Leckstroem","year":"2014","journal-title":"Expert Rev Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib8","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.ajkd.2003.12.003","article-title":"Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy","volume":"43","author":"Martin","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S2213-8587(14)70059-2","article-title":"Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders","volume":"2","author":"Vervloet","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib11","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.2215\/CJN.06300613","article-title":"Fracture risk in CKD","volume":"8","author":"Ensrud","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib12","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.2215\/CJN.09130912","article-title":"Estimated GFR and fracture risk: a population-based study","volume":"8","author":"Elliott","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib13","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.2215\/CJN.10901012","article-title":"Temporal trends in the incidence, treatment, and outcomes of hip fracture in older patients initiating dialysis in the United States","volume":"8","author":"Nair","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib14","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.2215\/CJN.02640310","article-title":"Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the \"trade-off\" hypothesis","volume":"5","author":"Gutierrez","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/ki.2009.464","article-title":"Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease","volume":"77","author":"Galitzer","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib16","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(73)92197-1","article-title":"Failure of formation of 1,25-dihydroxycholecalciferol in chronic renal insufficiency","volume":"1","author":"Mawer","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib17","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1046\/j.1523-1755.1999.0550031019.x","article-title":"Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure","volume":"55","author":"Ishimura","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1172\/JCI110586","article-title":"Metabolic acidosis suppresses 25-hydroxyvitamin in D3-1alpha-hydroxylase in the rat kidney. Distinct site and mechanism of action","volume":"70","author":"Kawashima","year":"1982","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib19","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","article-title":"Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease","volume":"16","author":"Gutierrez","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2215\/CJN.09580911","article-title":"PTH - a particularly tricky hormone: why measure it at all in kidney patients?","volume":"8","author":"Garrett","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/oxfordjournals.bmb.a069572","article-title":"Azotaemic renal osteodystrophy","volume":"13","author":"Stanbury","year":"1957","journal-title":"Br Med Bull"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib22","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ki.1979.25","article-title":"Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization","volume":"15","author":"Fournier","year":"1979","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib23","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/bmj.310.6976.358","article-title":"Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure","volume":"310","author":"Hamdy","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib24","first-page":"185","article-title":"Controlled trial of calcitriol in hemodialysis patients","volume":"26","author":"Baker","year":"1986","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib25","article-title":"Vitamin D compounds for people with chronic kidney disease requiring dialysis","volume":"4","author":"Palmer","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib26","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-147-12-200712180-00004","article-title":"Meta-analysis: vitamin D compounds in chronic kidney disease","volume":"147","author":"Palmer","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib27","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/MNH.0b013e3283470450","article-title":"Optimal vitamin D, calcitriol, and vitamin D analogue replacement in chronic kidney disease: to D or not to D: that is the question","volume":"20","author":"Moorthi","year":"2011","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.03940510","article-title":"Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials","volume":"6","author":"Kandula","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib29","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/ndt\/gft368","article-title":"Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?","volume":"29","author":"Liabeuf","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib30","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/bcp.12014","article-title":"Regression of vascular calcification in chronic kidney disease - feasible or fantasy? a review of the clinical evidence","volume":"76","author":"Leonard","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib31","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2174\/1389450115666140417120902","article-title":"Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease","volume":"15","author":"Donate-Correa","year":"2014","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsbmb.2013.11.007","article-title":"New vitamin D less-calcemic analog affect human bone cell line and cultured vascular smooth muscle cells similar to other less-calcemic analogs","volume":"140","author":"Somjen","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib33","doi-asserted-by":"crossref","first-page":"F1136","DOI":"10.1152\/ajprenal.00684.2011","article-title":"In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt\/\u03b2-catenin activation","volume":"303","author":"Mart\u00ednez-Moreno","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.numecd.2012.03.010","article-title":"Vitamin D receptor activation and prevention of arterial ageing","volume":"22","author":"Cozzolino","year":"2012","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib35","doi-asserted-by":"crossref","first-page":"c187","DOI":"10.1159\/000317198","article-title":"The effects of vitamin D therapy on left ventricular structure and function - are these the underlying explanations for improved CKD patient survival?","volume":"116","author":"Covic","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib36","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1093\/ndt\/gft268","article-title":"Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis","volume":"28","author":"Panizo","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib37","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000266204","article-title":"Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients","volume":"31","author":"Lund","year":"2010","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib38","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.ki.5001868","article-title":"Medical Directors of Dialysis Clinic Inc. Mortality risk among hemodialysis patients receiving different vitamin D analogs","volume":"70","author":"Tentori","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib39","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib40","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4196\/kjpp.2013.17.5.435","article-title":"Anti-apoptotic effect of paricalcitol in gentamicin-induced kidney injury","volume":"17","author":"Suh","year":"2013","journal-title":"Korean J Physiol Pharmacol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib41","doi-asserted-by":"crossref","first-page":"F301","DOI":"10.1152\/ajprenal.00471.2009","article-title":"Renoprotective effects of paricalcitol on gentamicin-induced kidney injury in rats","volume":"298","author":"Park","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib42","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jsbmb.2012.06.004","article-title":"The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload","volume":"132","author":"Meems","year":"2012","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib43","doi-asserted-by":"crossref","first-page":"F141","DOI":"10.1152\/ajprenal.00293.2011","article-title":"Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats","volume":"302","author":"Finch","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib44","doi-asserted-by":"crossref","first-page":"F647","DOI":"10.1152\/ajprenal.00090.2011","article-title":"Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy","volume":"302","author":"Sanchez-Ni\u00f1o","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib45","doi-asserted-by":"crossref","first-page":"622","DOI":"10.2353\/ajpath.2010.091292","article-title":"Therapeutic effects of vitamin D analogues on cardiac hypertrophy in spontaneously hypertensive rats","volume":"177","author":"Kong","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib46","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1159\/000178251","article-title":"Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats","volume":"29","author":"Husain","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib47","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.ki.5002406","article-title":"Differential effects of vitamin D receptor activators on vascular calcification in uremic rats","volume":"72","author":"Mizobuchi","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib48","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jsbmb.2010.03.026","article-title":"Myocardial effects of VDR activators in renal failure","volume":"121","author":"Mizobuchi","year":"2010","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib49","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.070305","article-title":"Differential effects of vitamin D analogs on vascular calcification","volume":"22","author":"Card\u00fas","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib50","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/1471-2369-14-199","article-title":"Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies","volume":"14","author":"Zheng","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib51","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/pds.3349","article-title":"Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis","volume":"21","author":"Miller","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib52","first-page":"B4400","article-title":"A randomised clinical study of alfacalcidol and paricalcitol","volume":"59","author":"Hansen","year":"2012","journal-title":"Dan Med J"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib53","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2215\/CJN.03000311","article-title":"Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis","volume":"7","author":"Cheng","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2369-10-28","article-title":"Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol","volume":"10","author":"Hansen","year":"2009","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib55","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/sj.ki.5002208","article-title":"Survival differences between activated injectable vitamin D2 and D3 analogs","volume":"71","author":"Kalantar-Zadeh","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib56","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial","volume":"376","author":"de Zeeuw","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib57","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1681\/ASN.2013030203","article-title":"Active vitamin D treatment for reduction of residual proteinuria: a systematic review","volume":"24","author":"de Borst","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib58","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.ahj.2012.09.018","article-title":"Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease","volume":"164","author":"Tamez","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib59","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial","volume":"307","author":"Thadhani","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2014.10.002_bib60","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1681\/ASN.2013010103","article-title":"Effect of paricalcitol on left ventricular mass and function in CKD\u2014the OPERA trial","volume":"25","author":"Wang","year":"2014","journal-title":"J Am Soc Nephrol"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929514001569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929514001569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T23:16:44Z","timestamp":1717629404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929514001569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0270929514001569"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2014.10.002","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}